企業プロフィール
Cocrystal Pharma 株価・ニュース・カタリスト
- ティッカー:
- COCP
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
1.09 USD (-2.68%)
終値
最終更新: 2026年8月17日
14.5M USD
時価総額
株価変動の要因
Following the latest company update, “Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors”, COCP closed down 2.68% at $1.09 on Aug 17, 2026. The move occurred in the trading session associated with this company update.
企業概要
Broad-Spectrum Antiviral Developer
Cocrystal Pharma uses a structure-based drug discovery platform to develop broad-spectrum antiviral medicines targeting conserved regions of viral proteases and polymerases. The strategy is intended to maintain activity across viral variants while minimizing off-target effects.
CDI-988 Norovirus Program
CDI-988 is an oral antiviral candidate for norovirus being evaluated in a Phase 1b human challenge study conducted with Emory University and the University of North Carolina. The trial includes both prevention and treatment cohorts.
Human Challenge Development Model
The controlled human infection study is designed to measure symptom incidence, viral shedding, safety, and pharmacokinetics in a defined setting. This approach can generate early proof-of-concept evidence for both prophylactic and therapeutic use.
Influenza and Coronavirus Pipeline
CC-42344 is a PB2 inhibitor for pandemic and seasonal influenza A. Cocrystal is also developing an inhaled formulation and generating leads for influenza A and B, while CDI-988 may have applications in coronavirus infections.
今後のカタリスト
- The CDI-988 Phase 1b human challenge study has completed the infectivity cohort and begun prevention and treatment cohorts; symptom incidence, viral shedding, safety, and pharmacokinetic results are the key upcoming readouts.
- An additional Phase 2a study of oral CC-42344 in influenza A is planned.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。